Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
Janet S. Graham, Ruth Plummer, Candice McCoy, Kristin Kowal, Herbert Wiesinger, Katharina Detjen, Hilary Calvert, Bertram Wiedenmann, Jim CassidyVolume:
44
Year:
2008
Language:
english
Pages:
2169
DOI:
10.1016/j.ejca.2008.06.006
File:
PDF, 152 KB
english, 2008